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Implication for health policy/practice/research/medical education:
In the last three decades, a variety of  clinical manifestations involving almost 
all organs and tissues (cardiac, pulmonary, neurological, renal, cutaneous, hae-
matologic, gastrointestinal, ocular, skeletal and endocrinologic), have been de-
scribed associated with antiphospholipid antibodies (aPL) . Nevertheless, the 
exact mechanism underlying the pathogenesis of  aPL-mediated damage has 
been poorly recognized. Inﬂammatory mechanisms beyond thrombosis have 
been proposed in some clinical presentations, suggesting a role for immuno-
modulation in therapeutic strategy.
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n the last three decades, a variety of  clinical 
manifestations involving almost all organs 
and tissues (cardiac, pulmonary, neurologi-
cal, renal, cutaneous, haematologic, gastrointes-
tinal, ocular, skeletal and endocrinologic), have 
been described associated with antiphospholip-
id antibodies (aPL) (1). Nevertheless, the exact 
mechanism underlying the pathogenesis of  aPL-
mediated damage has been poorly recognized. 
Inﬂammatory mechanisms beyond thrombosis 
have been proposed in some clinical presenta-
tions, suggesting a role for immunomodulation 
in therapeutic strategy (2). 
 This interesting case-report by Ardalan et al. (3) 
deﬁnitely illustrates the multiple expressions of  this 
disease. Although the classical criteria included in 
the revised classiﬁcation for antiphospholipid syn-
drome (APS), pregnancy morbidity or thrombosis 
and persistence of  positive aPL (4) were not pres-
ent, clinical features such as thrombocytopenia, 
renal dysfunction and mitral valve regurgitation, 
undoubtedly support the diagnosis of  APS.  Motor 
neuropathy, a rare and recently described presen-
tation (5), added complexity to the diagnosis and 
highlights the importance of  a multidisciplinary 
approach of  these patients. Antiphospholipid syn-
drome is really a disease with protean faces.
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